Liposome Di-adjuvant E is a specialized liposomal adjuvant formulation designed for advanced vaccine research and development applications. Built on a cholesterol and phospholipid-based bilayer liposome structure, this product is engineered to support immune-response enhancement in experimental vaccine platforms. It contains QS-21 and 3D-MPLA, each at 50 µg/ml, making it highly relevant for modern adjuvant studies where precise formulation consistency is critical. This product is positioned for use in research-grade and GMP-grade environments, supporting development workflows in areas such as RSV vaccine research, malaria vaccine research, adult tuberculosis vaccine research, and other next-generation immunization programs. Its liposome-based architecture is intended to improve delivery and presentation of adjuvant components within vaccine formulations, which is why it is especially valuable in laboratory, pilot-scale, and translational settings. For B2B buyers sourcing vaccine research reagents, liposomal adjuvant systems, or GMP-compliant formulation inputs, Liposome Di-adjuvant E offers a targeted solution with well-defined composition and application scope. It is best suited to organizations looking for export-ready, high-spec biological formulation materials for immunology, vaccine formulation optimization, and preclinical development. The combination of QS-21 and 3D-MPLA in a controlled liposomal matrix makes this product highly specific to advanced adjuvant research rather than general laboratory use.

*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.